{
  "uuid": "Guerrero-Murillo et al. (2024) bioRxiv",
  "short_id": "AISB-5",
  "hypothesis": "In this study, the authors investigate the immune response dynamics of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The main goal was to identify factors that drive the therapeutic efficacy of CAR-T cells, focusing on the differences between CAR-positive (CARpos) and CAR-negative (CARneg) T cells. The authors integrated single-cell transcriptomic and clonal data to explore the behavior of both CARpos and CARneg T cells, tracking their response across different time points\u2014specifically in the infusion product (IP) and at the peak of CAR-T cell expansion post-infusion.\n\nThe sequencing data consist of single-cell RNA sequencing (scRNA-seq) and single-cell T-cell receptor sequencing (sc-\u03b1\u03b2TCR-seq), which were used to analyze 38,190 T cells from five B-ALL patients. The dataset included CARpos and CARneg T cell populations from both the IP and peak expansion phases. The study provides valuable insights into the transcriptional profiles, clonal diversity, and functional states of these cells.",
  "result": "The dataset information are provided in the hypothesis.",
  "answer": true,
  "categories": "['RNA-seq', 'Differential Expression Analysis', 'Transcriptomics', 'Network Biology']",
  "paper": "10.1101/2024.01.23.576878",
  "questions": "[{'id': 'q2', 'development': '', 'question': 'Which T cell subset was significantly expanded at the peak of CAR-T cell expansion in the data?', 'ideal_answer': 'A) CD4+ T cells', 'distractor_1': 'B) \u03b3\u03b4T cells', 'distractor_2': 'C) CD8+ effector cytotoxic T cells', 'distractor_3': 'D) CD4+ effector memory T cells', 'explanation': ''}, {'id': 'q3', 'development': '', 'question': 'What did the data reveal about the CD4:CD8 ratio in CARpos T cells at the expansion peak?', 'ideal_answer': 'A) It was higher than in the infusion product (IP).', 'distractor_1': 'B) It was significantly lower than in the infusion product (IP).', 'distractor_2': 'C) It remained constant during expansion.', 'distractor_3': 'D) It was unrelated to clinical outcomes.', 'explanation': ''}, {'id': 'q4', 'development': '', 'question': 'Which of the following is true regarding the \u03b3\u03b4T cell population in the data?', 'ideal_answer': 'A) \u03b3\u03b4T cells lacked \u03b1\u03b2TCR and were expanded at the peak.', 'distractor_1': 'B) \u03b3\u03b4T cells were a minor population in both CARpos and CARneg fractions.', 'distractor_2': 'C) \u03b3\u03b4T cells were exclusively detected in CARneg populations.', 'distractor_3': 'D) \u03b3\u03b4T cells exhibited low cytotoxic activity at the expansion peak.', 'explanation': ''}, {'id': 'q5', 'development': '', 'question': 'What was the association between T cell exhaustion signatures and patient outcomes?', 'ideal_answer': 'A) Higher exhaustion scores were linked to better clinical outcomes.', 'distractor_1': 'B) Higher exhaustion scores were associated with early relapse in patients.', 'distractor_2': 'C) Exhaustion scores were unrelated to relapse or survival.', 'distractor_3': 'D) Lower exhaustion scores were associated with early relapse.', 'explanation': ''}]",
  "data_folder": "Guerrero-Murillo et al. (2024) bioRxiv.zip"
}